COLO-B 📈 Coloplast - Overview
Exchange: CO • Country: Denmark • Currency: DKK • Type: Common Stock • ISIN: DK0060448595
COLO-B: Ostomy, Catheters, Wound, Skin, Urology, Voice, Respiratory
Coloplast A/S is a company that specializes in the development and sale of intimate healthcare products and services, catering to a wide range of needs across various countries, including Denmark, the United States, the United Kingdom, France, and other international markets. The company's operations are divided into several segments, including Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care, each focusing on specific aspects of healthcare. For instance, the Chronic Care segment offers solutions for patients with long-term conditions, while the Continence Care segment provides products for individuals with urinary or fecal incontinence.
The company's product portfolio includes ostomy care solutions, such as SenSura Mio, which is designed to fit individual body shapes and provide optimal discretion for various types of ostomies. Additionally, Coloplast offers a range of ostomy accessories under the Brava brand, as well as continence care products like Conveen Active urine bags and SpeediCath catheters, which facilitate catheterization for both men and women. The Peristeen Plus transanal irrigation system is another product that helps individuals with bowel dysfunction. These products are designed to improve the quality of life for patients with intimate healthcare needs, enabling them to manage their conditions with dignity and confidence.
Coloplast also provides wound care products, including conforming dressings under the Biatain Silicone brand and hydrocolloid dressings under the Comfeel brand. The company's skin care products comprise a range of cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Furthermore, Coloplast develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. These products are designed to address specific medical conditions, providing effective solutions for patients and healthcare professionals.
In the area of voice and respiratory care, Coloplast offers laryngectomy care products, including Provox, a voice prosthesis for speaking, as well as heat and moisture exchangers (HMEs), adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories. The company also provides tracheostomy care products under the Tracoe brand, catering to the needs of patients with respiratory conditions. With a history dating back to 1954, Coloplast A/S is headquartered in Humlebæk, Denmark, and is listed on the stock exchange with the ISIN code DK0060448595, classified as a common stock under the GICS Sub Industry: Health Care Equipment.
Additional Sources for COLO-B Stock
COLO-B Stock Overview
Market Cap in USD | 24,899m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception |
COLO-B Stock Ratings
Growth 5y | -9.74% |
Fundamental | 60.9% |
Dividend | 53.1% |
Rel. Strength Industry | 47.8 |
Analysts | - |
Fair Price Momentum | 752.35 DKK |
Fair Price DCF | 183.68 DKK |
COLO-B Dividends
Dividend Yield 12m | 2.76% |
Yield on Cost 5y | 2.90% |
Annual Growth 5y | 4.10% |
Payout Consistency | 99.9% |
COLO-B Growth Ratios
Growth Correlation 3m | -71.7% |
Growth Correlation 12m | 3.3% |
Growth Correlation 5y | -38.2% |
CAGR 5y | 0.60% |
CAGR/Mean DD 5y | 0.03 |
Sharpe Ratio 12m | -0.10 |
Alpha | -13.50 |
Beta | 0.41 |
Volatility | 23.94% |
Current Volume | 239.8k |
Average Volume 20d | 207.9k |
As of January 15, 2025, the stock is trading at DKK 792.00 with a total of 239,844 shares traded.
Over the past week, the price has changed by +2.10%, over one month by -3.32%, over three months by -8.74% and over the past year by +4.26%.
Yes, based on ValueRay Fundamental Analyses, Coloplast (CO:COLO-B) is currently (January 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 60.89 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of COLO-B as of January 2025 is 752.35. This means that COLO-B is currently overvalued and has a potential downside of -5.01%.
Coloplast has no consensus analysts rating.
According to ValueRays Forecast Model, COLO-B Coloplast will be worth about 817 in January 2026. The stock is currently trading at 792.00. This means that the stock has a potential upside of +3.15%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 924.4 | 16.7% |
Analysts Target Price | - | - |
ValueRay Target Price | 817 | 3.2% |